Core Viewpoint - Edwards Lifesciences Corp. is expected to report strong fourth-quarter 2025 results, with revenue and earnings estimates indicating significant year-over-year growth [1][9]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues is $1.54 billion, reflecting an 11.1% increase from the previous year [2]. - The earnings estimate is set at 62 cents per share, indicating a 5.1% rise from the year-ago figure [2]. - The company has consistently beaten earnings estimates in the past four quarters, with an average surprise of 8.89% [1]. Group 2: Segment Performance - The Transcatheter Aortic Valve Replacement (TAVR) segment is projected to generate $1.13 billion in sales, representing an 8.6% year-over-year increase, driven by strong performance and clinical community focus [6][9]. - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is expected to see revenues of $151.6 million, implying a 44.2% improvement from the previous year, supported by the PASCAL, EVOQUE, and SAPIEN M3 systems [10][9]. - The Surgical Structural Heart segment is estimated to generate $259.8 million, suggesting a modest 6.3% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [12][11]. Group 3: Market Trends and Guidance - Edwards has raised its 2025 sales growth guidance for the TAVR segment to 7-8%, up from the previous 6-7% [6]. - The company is expected to benefit from global procedure growth and expanded education in the TAVR market, particularly in the U.S. [4][5]. - The recent FDA approval of the SAPIEN M3 mitral valve replacement system is anticipated to contribute positively to the company's top-line growth [8].

Group 1 - Edwards Lifesciences Corporation (NYSE:EW) is considered one of the best healthcare stocks to buy for 2026, with Stifel raising its price target to $110 from $105 while maintaining a Buy rating [1] - The price target increase is attributed to a significant rise in Transcatheter Aortic Valve Replacement (TAVR) procedures, indicating strong growth in the TAVR market fundamentals [2] - The company's revenue grew by 10% in the third quarter, primarily driven by the TAVR division, which constitutes 75% of total revenue, marking the strongest growth for this division in recent years [2] Group 2 - On January 9, TD Cowen upgraded Edwards Lifesciences to a Buy from Hold and raised the price target to $97 from $90, citing a renewed growth cycle driven by expanded indications for TAVR [3] - Edwards Lifesciences is a medical technology company focused on innovations for heart conditions, specializing in structural heart disease and critical care monitoring [4]

Core Insights - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Edwards Lifesciences Corporation and may file a class action on behalf of affected investors [1][2] Financial Performance - On July 24, 2024, Edwards reported second-quarter financial results for fiscal 2024 that were below expectations and reduced its full-year 2024 revenue guidance for its Transcatheter Aortic Valve Replacement (TAVR) platform [3] - The slowdown in TAVR was attributed to the growth of structural heart therapies, which impacted hospital workflows and led to underutilization of TAVR despite claims of a significantly undertreated patient population [3] - Edwards announced three acquisitions during the quarter aimed at enhancing treatments alternative to TAVR, indicating awareness of the decelerating growth of the TAVR platform [3] Stock Market Reaction - Following the disappointing disclosures, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in a single trading day [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].

Core Insights - Edwards Lifesciences reported strong second-quarter 2025 earnings, surpassing revenue and earnings expectations, primarily driven by growth in heart valve therapies [1][2][3] Financial Performance - The company achieved sales of $1.53 billion, exceeding the consensus estimate of $1.49 billion and falling within management's guidance of $1.45 billion to $1.53 billion [2] - Sales grew by 11.9%, or 10.6% when adjusted, with all product groups showing strength [3] - Adjusted earnings were reported at 67 cents per share, beating the consensus of 62 cents and management's guidance of 59 to 65 cents [3] Segment Performance - Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.1 billion, marking an increase of 8.9%, or 7.8% on a constant currency basis [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) segments reported sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or over 57.1% on a constant currency basis [5] - Surgical segment global sales reached $267 million, an increase of 7.7% year-over-year, or 6.8% on a constant currency basis [5] Guidance and Outlook - The company raised its full-year sales guidance from $5.70 billion to $6.10 billion to a new range of $5.90 billion to $6.10 billion, compared to the consensus of $5.91 billion [6] - Adjusted earnings guidance for fiscal 2025 is affirmed at $2.40 to $2.50 per share, with third-quarter adjusted earnings forecasted at 54 to 60 cents [7] - TAVR underlying growth rate guidance is increased to 6% to 7%, with sales guidance for TAVR set at $4.3 billion to $4.5 billion [8] Analyst Insights - Goldman Sachs views the second quarter as a turning point for the company, expecting steady double-digit revenue growth [9] - Analysts predict that Edwards will return to strong performance, with revenue growth over 10% and operating margins above 30% [11] - Various analysts have raised their price forecasts for Edwards Lifesciences, with Deutsche Bank increasing its target from $85 to $94, and Barclays raising its forecast from $90 to $95 [12][13][14]

Company Insights - Edwards Lifesciences announced new economic and clinical evidence on severe aortic stenosis (AS) at EuroPCR 2025, indicating that early intervention before symptoms develop can reduce healthcare costs by $36,000 per patient and improve patient outcomes [1][5] - The company has a market capitalization of $44.64 billion and an earnings yield of 3.2%, outperforming the industry average of -2.8% [4] - Edwards' stock closed at $74.79, down 1.7% from the previous close, but the company is expected to maintain positive market sentiment due to its commitment to TAVR innovation and strong clinician adoption of SAPIEN technology [3] Industry Insights - The AS treatment market is projected to reach $8.6 billion in 2024, with a compound annual growth rate (CAGR) of 7.4% by 2034, driven by advancements in medical technology and increased awareness among healthcare professionals and patients [7][8] - The recent FDA approval for the SAPIEN 3 platform for asymptomatic severe AS patients is based on data from the EARLY TAVR trial, which showed superior outcomes compared to traditional clinical surveillance [10] - The company continues to benefit from the strong uptake of its premium RESILIA portfolio in the surgical segment, which includes products like INSPIRIS, MITRIS, and KONECT [3]